BridgeBio Pharma released Phase 1/2 trial results for BBP-631, its gene therapy for congenital adrenal hyperplasia. The study ...

Parkinson's disease (PD) is a debilitating movement disorder that affects millions of individuals worldwide, especially older ...

PTC Therapeutics, Inc. got a dose-dependent lowering of mutant Huntingtin protein in both the blood and CSF of HD patients ...

The findings highlight the essential role of AGPs and other cell wall components in maintaining fruit quality. The study ...

Increase in endogenous cortisol production achieved in all patients in higher dose cohorts of BBP-631, a result seen for the first time ever in ...

One of the three genes, called tryptophan hydroxylase, or tph2, is also associated with mood disorders and suicide risk in humans. ‘To think that just a high-fat diet could alter expression of these ...

California, USA-based biotech BridgeBio Pharma saw its shares dip 4% to $29.60 yesterday on disappointing clinical results ...

The company said newly released Phase I/II study data for BBP-631 indicated the program did not merit further capital investment.

Additionally, it upregulated key Nurr1 target genes, such as tyrosine hydroxylase (TH) and vesicular monoamine transporter 2 (VMAT2), in human microglial and murine neuronal cell lines, which could ...

Bruck syndrome is a rare, autosomal-recessive condition associated with features of both arthrogryposis and osteogenesis imperfecta. It is characterised by congenital large joint contractures with ...